Proclaim DRG Neurostimulator System
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $429,980 | 339 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $429,980 | 339 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TARGET: A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II | Abbott Laboratories | $276,456 | 1 |
| PROLONG Prospective, Multi-center, Open-label, Post-market Study (PROLONG) | Abbott Laboratories | $153,523 | 0 |
Top Doctors Receiving Payments for Proclaim DRG Neurostimulator System
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charleston, WV | $429,152 | 337 |
| , MD, DABA, DAPM | Anesthesiology | New York, NY | $828.00 | 2 |
Manufacturing Companies
- Abbott Laboratories $429,980
Product Information
- Type Device
- Total Payments $429,980
- Total Doctors 1
- Transactions 339
About Proclaim DRG Neurostimulator System
Proclaim DRG Neurostimulator System is a device associated with $429,980 in payments to 1 healthcare providers, recorded across 339 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2020 to 2020. In 2020, $429,980 was paid across 339 transactions to 1 doctors.
The most common payment nature for Proclaim DRG Neurostimulator System is "Unspecified" ($429,980, 100.0% of total).
Proclaim DRG Neurostimulator System is associated with 2 research studies, including "TARGET: A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II" ($276,456).